



Disclosure of Remuneration for Non-Audit Services

October 22, 2020

Released : October 22, 2020 18:22

RNS Number : 9790C

MaxCyte, Inc.

22 October 2020

Disclosure of Remuneration for Non-Audit Services

Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an update to its previous disclosure of remuneration for audit-related services.

The Company previously disclosed on 14 October 2020 that the remuneration of the Company's auditors, Cohn Reznick LLC, for services relating to the 2019 financial year, amounted to approximately \$137,000.

In order to further assist investors in considering the resolutions proposed ahead of the Company AGM, MaxCyte advises that these fees consisted of \$119,000 for audit services and \$18,000 for tax services, with no further costs incurred for any other services.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more

than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

###

Contacts:

MaxCyte Inc.

+1 301-944-1660

Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

+44 (0)20 7886 2500

Emma Earl
Freddy Crossley

Corporate Broking

Rupert Dearden

Joint Corporate Broker

Numis Securities Limited

+44 (0)20 7260 1000

James Black
Duncan Monteith

Financial PR Adviser

+44 (0)203 709 5700

Consilium Strategic Communications

maxcyte@consilium-com

Mary-Jane Elliott
Chris Welsh

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the

personal data you provide us, please see our [Privacy Policy](#).

END

MSCKKBBBOBDDDKB